

## Infliximab Formulation - (OGN)

Version 2.2      Revision Date: 06.04.2024      SDS Number: 9875896-00007      Date of last issue: 30.09.2023  
Date of first issue: 19.10.2021

---

**Section 1: Identification**

**Product identifier** : Infliximab Formulation - (OGN)

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

**Manufacturer or supplier's details**

Company : Organon & Co.  
Address : 30 Hudson Street, 33rd floor  
Jersey City, New Jersey, U.S.A 07302  
Telephone : +1-551-430-6000  
Emergency telephone number : +1-215-631-6999  
E-mail address : EHSSTEWARD@organon.com

---

**Section 2: Hazard identification****Classification of the substance or mixture**

Not a hazardous substance or mixture.

**GHS Label elements, including precautionary statements**

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required

**Other hazards which do not result in classification**

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

---

**Section 3: Composition/information on ingredients**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Sucrose	57-50-1	>= 70 -< 90
Infliximab	170277-31-3	>= 10 -< 20

## Infliximab Formulation - (OGN)

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.2	06.04.2024	9875896-00007	Date of first issue: 19.10.2021

---

---

**Section 4: First-aid measures****Description of necessary first-aid measures**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.
- In case of skin contact : Wash with water and soap.  
Get medical attention if symptoms occur.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.

**Most important symptoms and effects, both acute and delayed**

- Risks : Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : No special precautions are necessary for first aid responders.

**Indication of any immediate medical attention and special treatment needed**

- Treatment : Treat symptomatically and supportively.
- 

**Section 5: Fire-fighting measures****Extinguishing media**

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.

**Special hazards arising from the substance or mixture**

- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides

**Special protective actions for fire-fighters**

- Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.  
Use personal protective equipment.
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
-

## Infliximab Formulation - (OGN)

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.2	06.04.2024	9875896-00007	Date of first issue: 19.10.2021

---

Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

**Section 6: Accidental release measures****Personal precautions, protective equipment and emergency procedures**

Personal precautions : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**Environmental precautions**

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

**Methods and materials for containment and cleaning up**

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

**Section 7: Handling and storage****Precautions for safe handling**

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.

---

## Infliximab Formulation - (OGN)

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.2	06.04.2024	9875896-00007	Date of first issue: 19.10.2021

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.

**Conditions for safe storage, including any incompatibilities**

Conditions for safe storage : Keep in properly labelled containers.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

**Section 8: Exposure controls/personal protection****Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Sucrose	57-50-1	PEL (long term)	10 mg/m <sup>3</sup>	SG OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Infliximab	170277-31-3	TWA	150 µg/m <sup>3</sup>	Internal

**Appropriate engineering control measures** : Ensure adequate ventilation, especially in confined areas.  
Minimize workplace exposure concentrations.  
Apply measures to prevent dust explosions.  
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

**Individual protection measures, such as personal protective equipment (PPE)**

Eye/face protection : Wear the following personal protective equipment:  
Safety goggles

Skin protection : Skin should be washed after contact.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : For prolonged or repeated contact use protective gloves.  
Wash hands before breaks and at the end of workday.

**Section 9: Physical and chemical properties**

# SAFETY DATA SHEET



## Infliximab Formulation - (OGN)



Version 2.2      Revision Date: 06.04.2024      SDS Number: 9875896-00007      Date of last issue: 30.09.2023  
Date of first issue: 19.10.2021

---

Appearance : Amorphous powder

Colour : white

Odour : No data available

Odour Threshold : No data available

pH : 7.2

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : 1 g/cm<sup>3</sup>

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : No data available

Explosive properties : Not explosive

# SAFETY DATA SHEET



## Infliximab Formulation - (OGN)



Version 2.2      Revision Date: 06.04.2024      SDS Number: 9875896-00007      Date of last issue: 30.09.2023  
Date of first issue: 19.10.2021

---

Oxidizing properties : The substance or mixture is not classified as oxidizing.  
Molecular weight : No data available  
Particle characteristics  
Particle size : No data available

---

### Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard.  
Chemical stability : Stable under normal conditions.  
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.  
Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.  
Incompatible materials : Oxidizing agents  
Hazardous decomposition products : No hazardous decomposition products are known.

---

### Section 11: Toxicological information

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### Sucrose:

Acute oral toxicity : LD50 (Rat): 29,700 mg/kg

#### Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### Infliximab:

Remarks : No data available

#### Serious eye damage/eye irritation

Not classified based on available information.

## Infliximab Formulation - (OGN)

Version 2.2      Revision Date: 06.04.2024      SDS Number: 9875896-00007      Date of last issue: 30.09.2023  
Date of first issue: 19.10.2021

---

### Components:

#### **Infliximab:**

Remarks : No data available

### **Respiratory or skin sensitisation**

#### **Skin sensitisation**

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

#### **Germ cell mutagenicity**

Not classified based on available information.

### Components:

#### **Sucrose:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative

#### **Infliximab:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Test Type: Chromosomal aberration  
Test system: human lymphoblastoid cells  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Method: OECD Test Guideline 474  
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

### **Carcinogenicity**

Not classified based on available information.

### **Reproductive toxicity**

Not classified based on available information.

### Components:

#### **Infliximab:**

Effects on fertility : Test Type: Fertility  
Species: Mouse  
Application Route: Intravenous injection  
Fertility: NOAEL: 40 mg/kg body weight

# SAFETY DATA SHEET



## Infliximab Formulation - (OGN)



Version 2.2      Revision Date: 06.04.2024      SDS Number: 9875896-00007      Date of last issue: 30.09.2023  
Date of first issue: 19.10.2021

---

Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Mouse, female  
Application Route: Intravenous injection  
Duration of Single Treatment: 6 - 12 d  
General Toxicity Maternal: NOAEL: 40 mg/kg body weight  
Teratogenicity: NOAEL F1: 40 mg/kg body weight  
Developmental Toxicity: NOAEL F1: 40  
Embryo-foetal toxicity: NOAEL: 40 mg/kg body weight  
Remarks: Based on data from similar materials

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

Not classified based on available information.

### Repeated dose toxicity

#### Components:

##### **Infliximab:**

Species : Mouse  
NOAEL : 40 mg/kg  
Application Route : Intravenous  
Exposure time : 6 Months  
Number of exposures : daily

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

##### **Infliximab:**

Inhalation : Symptoms: Nausea, Vomiting, Abdominal pain, Diarrhoea, Fatigue, Headache, Back pain

---

## Section 12: Ecological information

### Toxicity

#### Components:

##### **Infliximab:**

### Ecotoxicology Assessment

Acute aquatic toxicity : No data available  
Chronic aquatic toxicity : No data available



## Infliximab Formulation - (OGN)

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.2	06.04.2024	9875896-00007	Date of first issue: 19.10.2021

---

**Persistence and degradability**

No data available

**Bioaccumulative potential****Components:****Sucrose:**Partition coefficient: n- : Pow: < 1  
octanol/water**Mobility in soil**

No data available

**Other adverse effects**

No data available

---

**Section 13: Disposal considerations****Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

**Section 14: Transport information****International Regulations****UNRTDG**

UN number	:	Not applicable
UN proper shipping name	:	Not applicable
Transport hazard class(es)	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Environmentally hazardous	:	no

**IATA-DGR**

UN/ID No.	:	Not applicable
UN proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable
Packing instruction (passenger aircraft)	:	Not applicable

**IMDG-Code**

## Infliximab Formulation - (OGN)

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.2	06.04.2024	9875896-00007	Date of first issue: 19.10.2021

---

UN number : Not applicable  
UN proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
EmS Code : Not applicable  
Marine pollutant : Not applicable

**Transport in bulk according to IMO instruments**

Not applicable for product as supplied.

**Special precautions for user**

Not applicable

---

**Section 15: Regulatory information****Safety, health and environmental regulations specific for the product in question**

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and : Not applicable  
Environmental Protection and Management (Hazardous Substances) Regulations

Fire Safety (Petroleum and Flammable Materials) : Not applicable  
Regulations

**The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

---

**Section 16: Other information**

Revision Date : 06.04.2024

**Further information**

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD  
compile the Safety Data eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>  
Sheet

Date format : dd.mm.yyyy

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
SG OEL : Singapore. Workplace Safety and Health (General Provisions)  
Regulations - First Schedule Permissible Exposure Limits of

---

# SAFETY DATA SHEET



## Infliximab Formulation - (OGN)



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.2	06.04.2024	9875896-00007	Date of first issue: 19.10.2021

---

### Toxic Substances.

ACGIH / TWA : 8-hour, time-weighted average  
SG OEL / PEL (long term) : Permissible Exposure Level (PEL) Long Term

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN